Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | NCF1 | P14598 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7224310 | 0.85 | CYP1A2 (0.56) | CYP1A2NCF1KDM4EUSP2ALDH1A1 | |
| SCHEMBL21316068 | 0.83 | CYP1A2 (0.58) | CYP1A2NCF1KDM4EUSP2ALDH1A1 | |
| SCHEMBL13991803 | 0.81 | CYP1A2 (0.56) | CYP1A2NCF1KDM4EUSP2ALDH1A1 | |
| SCHEMBL12390044 | 0.81 | CYP1A2 (0.41) | CYP1A2NCF1KDM4EALDH1A1HPGD | |
| SCHEMBL7379490 | 0.80 | CYP1A2 (0.55) | CYP1A2NCF1KDM4EUSP2ALDH1A1 | |
| SCHEMBL19724363 | 0.80 | NCF1 (0.56) | CYP1A2NCF1KDM4EUSP2ALDH1A1 | |
| SCHEMBL13684731 | 0.79 | CYP1A2 (0.47) | CYP1A2KDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL1577322 | 0.79 | LMNA (0.50) | CYP1A2KDM4EUSP2ALDH1A1MAPT | |
| SCHEMBL10330489 | 0.79 | BACE1 (0.59) | CYP1A2NCF1KDM4EALDH1A1MAPT | |
| SCHEMBL1577721 | 0.79 | GABRA1 (0.41) | CYP1A2NCF1MAPTHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-115710199-B | Photooxidation reduction catalytic process | 深圳湾实验室坪山生物医药研发转化中心 | 2024-06-28 | — | — | CN | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| CN-115108980-B | Preparation method of No. 4 acylated derivative of 2-methylquinoline compound | 济南大学 | 2023-06-16 | — | — | CN | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| CN-114380741-B | Preparation method of 4-position alkylated derivative of 2-methylquinoline compound | 济南大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-115710199-A | Photo-oxidation-reduction catalysis method | 深圳湾实验室坪山生物医药研发转化中心 | 2023-02-24 | — | — | CN | disclosed |
| CN-113387837-B | Photo-oxidation-reduction catalysis method | 深圳湾实验室坪山生物医药研发转化中心 | 2023-02-21 | — | — | CN | disclosed |
| EP-4115882-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | The General Hospital Corporation (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-115108980-A | Preparation method of 4-bit acylated derivative of 2-methylquinoline compound | 济南大学 | 2022-09-27 | — | — | CN | disclosed |
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130131073-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME CORP. | 2013-05-23 | — | — | US | disclosed |
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| WO-2012018662-A2 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | SCHERING CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20120022097-A1 | Compositions and Methods for Treating Cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022097-A1 | Compositions and Methods for Treating Cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| WO-2009155448-A1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | LIGAND PHARMACEUTICALS INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009143178-A2 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPS4Y1 | CYP1A2 1485/4885NCF1 544/4885KDM4E 3155/4885 |
| US-20130131073-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPS4Y1 | CYP1A2 690/4885NCF1 299/4885KDM4E 4027/4885 |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CHEK2, CHEK1, PLK1 | CYP1A2 1846/4885NCF1 2817/4885KDM4E 1238/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP1A2 540/4885NCF1 4234/4885KDM4E 2437/4885 |
| US-20120022097-A1 | Compositions and Methods for Treating Cancer | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A | CYP1A2 945/4885NCF1 2313/4885KDM4E 1359/4885 |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | CYP1A2 178/4885NCF1 3876/4885KDM4E 1597/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CYP1A2 540/4885NCF1 4234/4885KDM4E 2437/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP1A2 4271/4885NCF1 966/4885KDM4E 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.